Have you been considering a one-armed observational study or asked to work on such a study? As a statistician, it is important to understand the scientific but even more the political background of such studies. In this episode, we will discuss one-armed observational studies and why they are, in most cases, not a good idea. …
The world of healthcare continues to change, and it’s important to keep up with the latest advances in technology and research. That’s why I’m excited to talk with Shirley Wang, one of the leaders of RCT Duplicate, a study focused on duplicating randomized clinical trials through real world data. She is currently leading the RCT Duplicate as the …
Today I’m talking with Rachel Tham, a principal statistician, about a book that has been incredibly impactful in both of our lives—Deep Work. We discuss what deep work is and how it can help statisticians at work. Deep work is a concept developed by Cal Newport which encourages people to focus intensely on one task …
Why are companies often running single arm studies in development? What are the potential drawbacks and why is it not a binary choice between full comparative study and single arm trial? What are solutions in between to find a balance between feasibility and rigour? Single arm studies are a popular method for collecting data despite …
Reproducible research is a key part of research in the pharma industry. It allows for transparency, understanding, and accuracy in the research process. But how can you make your research more reproducible? Today, I talk with Heidi Seibold who has dedicated her career to helping researchers become more reproducible. Let’s take a look at 3 …
Are you a statistician working in the pharmaceutical industry and never got in touch with economic modelling and network meta-analyses? Then you should listen to this episode! The EU HTA will not only affect all statisticians in the pharmaceutical industry with respect to skill sets and collaboration (we talked about that in podcast #3), but …
What will be the role of health economics in the future EU HTA? Read More »